This promotional website is for UK healthcare professionals involved in the care of patients with cancer. Adverse event reporting information can be found below.
VENCLYXTO® in Acute Myeloid Leukaemia (AML)
Indicated in combination with a hypomethylating agent for the treatment of adult patients
with newly diagnosed AML who are ineligible for intensive chemotherapy1
Explore Venclyxto data and resources
View on-demand content
View and download resources
Fill in a form to make an appointment with a representative
VENCLYXTO® in Acute Myeloid Leukaemia (AML)
Indicated in combination with a hypomethylating agent for the treatment of adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy1
Explore Venclyxto data and resources
View on-demand video content
View and download resources
Fill in a form to make an appointment with a representative
You are advised to read the Prescribing Information and Summary of Product Characteristics (GB SmPC; NI SmPC) to evaluate patient suitability for VENCLYXTO.
References
- VENCLYXTO Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on [email protected]
UK-VNCAML-240062. Date of preparation: April 2024.
